Tissue Plasminogen Activator (tPA) Antigen
Synonyms |
|
||||||||||||
Cerner Name |
|||||||||||||
Clinical Info |
As the primary mediator of endogenous fibrinolysis, elevated tPA levels are strongly associated with an increased risk of arterial vascular disease and have been shown to indicate risk of future myocardial infarction. |
||||||||||||
Specimen Sources |
Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous |
||||||||||||
Specimen Types |
Blood |
||||||||||||
Specimen Volume |
1mL citrated plasma |
||||||||||||
Container |
Blue Top Tube |
||||||||||||
Collection Instructions |
Container/Tube: Blue-top (3.2% sodium citrate) tube |
||||||||||||
Transport Instructions |
Frozen |
||||||||||||
Specimen Stability |
|||||||||||||
Methodology |
Tissue plasminogen activator is bound to the wells of a microtiter plate by anti-tPA monoclonal antibodies. Unbound material is washed out of the wells. Bound tPA converts a chromogenic substrate to produce color. |
||||||||||||
Days Performed |
|||||||||||||
Performing Laboratories |
Labcorp-Esoterix |
||||||||||||
CPT |
85415 |
||||||||||||
PDM |
5600600 |
||||||||||||
Results |
|
||||||||||||
Result Interpretation
< 14.1 ng/mL
|
|||||||||||||
Forms |
|
||||||||||||

